Overview of Dermacrin A 1%

Property	Description
Active ingredient	Enoxolone (Glycyrrhetinic acid)
Form	Ointment
Pharmacological class	Dermatological Anti-Inflammatory Agent
Route	Topical (Skin Application)
Origin	Natural Derivative (Glycyrrhiza glabra)

What is Dermacrin A 1% and What Type of Medicine is It?

Dermacrin A 1% is a prescription topical pharmaceutical preparation marketed as a dermatological anti-inflammatory agent, typically formulated as a semi-solid ointment. This product is a single-ingredient formulation, defined by its 1% concentration of the sole active ingredient, Enoxolone, which is intended for application directly to the skin surface. The drug's classification in the Anatomical Therapeutic Chemical (ATC) system places it under the code D03AX10, identifying it as an Other Cicatrizant within the overarching group of Dermatologicals. Its specific presentation as an ointment distinguishes it as a preferred option for dry, irritated skin conditions that benefit from the additional moisturizing and protective layer of an occlusive vehicle.

Enoxolone: Composition, Origin, and Pharmacological Class

The active component, Enoxolone, is scientifically known as Glycyrrhetinic acid or 18beta-Glycyrrhetinic acid. This compound is structurally defined as a pentacyclic triterpenoid derivative. This molecule is a natural derivative because it functions as a bioactive metabolite of glycyrrhizin, which is extracted from the root of the licorice plant (Glycyrrhiza glabra). The use of Enoxolone in dermatology is characterized by its local activity in the epidermal layer.

General Purpose: Relief of Skin Irritation

The general purpose of Dermacrin A 1% is to provide relief from the core symptoms of skin irritation through its anti-inflammatory action. Enoxolone is associated with the reduction of inflammation and the stabilization of cell membranes when applied topically. The medicine helps to calm the irritated area and minimize skin reactivity. The compound operates by modulating specific inflammatory pathways, such as by influencing the enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) locally in the skin. The fundamental benefit is the reduction of key physical manifestations of skin irritation, including erythema (redness) and edema (swelling), alongside the targeted alleviation of dermal pruritus (itching) often seen in cases of superficial dermatoses.

What side effects are possible with Dermacrin A 1%?

Possible Side Effects and Safety Information

The safety profile of Dermacrin A 1% (Enoxolone) is based on the documented local effects of the ointment and the known systemic properties of the active molecule, as detailed in regulatory documents.

Dermatological Reactions and Frequency

Adverse events associated with the application of topical Enoxolone primarily affect the Skin and Subcutaneous Tissue Disorders system-organ class. The main adverse event documented in official regulatory text is local irritation at the site of application. This may manifest as temporary redness or discomfort. The precise frequency of this local irritation is typically classified as Not Known for this specific single-agent topical formulation, though regulatory notes indicate that the effect, when it occurs, is usually temporary in nature.

Administration-Agnostic Systemic Safety Constraints

The molecule Enoxolone (Glycyrrhetinic acid) is associated with a critical administration-agnostic safety profile related to its effect on the enzyme 11-beta-hydroxysteroid dehydrogenase type 2. Systemic exposure is linked to the potential for a condition resembling pseudohyperaldosteronism. This high-level safety constraint involves the risk of sodium and water retention, which can lead to increased blood pressure (hypertension), and a reduction in blood potassium levels (hypokalemia). While systemic absorption from standard topical use is generally minimal, this risk is a fundamental safety characteristic of the compound.

Safety Considerations for Specific Groups

Official regulatory assessments have noted specific cautions regarding the use of Enoxolone in certain populations. Individuals with pre-existing cardiovascular disorders, such as hypertension, should note the potential, though low, for systemic effects. Furthermore, regulatory bodies have expressed cautions regarding the use of Enoxolone in children and in women who are pregnant or breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

The official information for Dermacrin A 1% ointment provides a specific instruction regarding the possibility of accidental use beyond the prescribed amount. This instruction is the primary guidance for an overdose situation as defined in the regulatory documents.

Official Guidance for Accidental Overuse

If you have accidentally used more than the prescribed dose of Dermacrin A 1%, you should immediately consult with your doctor or pharmacist.

Regulatory information does not explicitly describe a detailed profile of overdose symptoms or adverse presentations in the overdose section. No specific clinical manifestations, physiological systems affected, or severity classifications are detailed in the available regulatory consumer documents concerning the overuse of this medicine.

Overdose Scenario	Required Action (Official Statement)
Accidental use of more than the prescribed dose	Consult with your doctor or pharmacist.

This instruction serves as the required emergency action mentioned in official patient information. No further procedural instructions or statements requiring urgent medical attention (such as calling emergency services) are explicitly included in the official overdose warnings. The information emphasizes the need to communicate with a healthcare professional if accidental overuse occurs.

Therapeutic Uses of Dermacrin A 1%

Dermacrin A 1% is a topical medication used in situations involving certain distressing symptoms related to localized skin inflammation, providing supportive symptomatic relief. Its use is centered on anti-inflammatory and antipruritic effects in various skin disorders.

Symptom Relief and Therapeutic Context

The ointment is applied to manage symptoms of various superficial dermatoses, including episodic manifestations of atopic dermatitis, contact dermatitis, and the redness associated with mild seborrheic dermatitis. It targets the visible signs of irritation, such as intense erythema (redness) and local edema (swelling), and helps address symptoms related to inflammatory or irritative states during periods of heightened symptoms. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

The medication is commonly used to help with distressing sensory discomfort, particularly persistent pruritus (itching) along with sensations of burning and stinging. This action is relevant in contexts like irritative reactions or when soothing is required after sun exposure, and contributes to improved comfort during symptomatic periods. The product is relevant for easing symptoms related to inflammatory or irritative states.

Quick Facts

Category	Description
Therapeutic Scope	Used for managing symptoms in conditions involving inflammatory or irritative processes.
Primary Benefit	Helps ease the overall symptom burden, particularly pruritus and redness.
Clinical Context	Applied when supportive symptom management is appropriate for mild-to-moderate flares.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermacrin A 1%

This section outlines the official population eligibility and non-eligibility for Dermacrin A 1% (topical Enoxolone 1%), strictly based on governmental regulatory labeling. Eligibility is defined by absolute contraindications, restrictions, and the availability of safety data for specific groups.

Official Eligibility Status

Classification	Population Group
Contraindicated	Patients with known hypersensitivity or allergy to the active substance, Enoxolone (Glycyrrhetinic acid), or to any excipient in the ointment.
Use Allowed	Adults (18 years and older) who do not have any contraindications.
Not Recommended	Pregnant women, breastfeeding women, and pediatric patients (children and adolescents).

Population-Specific Restrictions

Pregnancy and Lactation: Use is not recommended in pregnant women or those who are breastfeeding. This caution is based on the lack of sufficient human safety data for the topical route and the known systemic risks associated with the molecule's parent compound.

Age-Related Eligibility: The safety and efficacy of this prescription topical formulation are generally not established in the pediatric population (children and adolescents). Use in these age groups is therefore not recommended by regulatory bodies.

Conditional Use: While the topical formulation has minimal systemic absorption, use may be considered conditional for patients with severe pre-existing systemic conditions, such as hypertension or renal impairment, especially if the ointment is applied over large surface areas or to broken skin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding interactions for Dermacrin A 1% emphasizes a general precaution against combining it with other medicinal products. The documented regulatory guidance highlights that co-administration may result in either the enhancement or diminution of the drug's intended medicinal effects. This necessitates a procedural requirement for interaction management.

Interaction Profile Summary

Interaction Type	Observed Effect (Regulatory Statement)	Required Action
Pharmacodynamic / Pharmacokinetic	Possible enhancement of effects	Inform doctor/pharmacist
Pharmacodynamic / Pharmacokinetic	Possible diminution of effects	Inform doctor/pharmacist
Specific Interacting Agents	None explicitly listed in regulatory documents	General caution

Regulatory Constraint

Regulatory authorities mandate that patients must inform their doctor and pharmacist of all other medicinal products they are currently taking. This requirement covers prescription medicines, over-the-counter drugs, and any other preparation that might influence the effects of Dermacrin A 1%. This procedural constraint ensures that healthcare professionals can assess the potential for interaction risks on a case-by-case basis before co-use. There are no explicitly stated timing-based rules or population-specific interaction notes documented in the core regulatory label.

Mechanism of Action

The mechanism of Dermacrin A 1% (Enoxolone) involves modulating the endogenous anti-inflammatory pathway at a molecular level within the skin, focusing on two core domains.

Regulation of Endogenous Cortisol Levels

The primary action of Enoxolone is the inhibition of the enzyme 11beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2). This enzyme converts the natural anti-inflammatory hormone, cortisol, to an inert form. By blocking this conversion, Enoxolone ensures a higher local concentration of active cortisol is available to signal through the Glucocorticoid Receptor ( GR), initiating a receptor-mediated regulatory sequence.

Suppression of Pro-Inflammatory Gene Transcription

The amplified cortisol signaling leads to the nuclear GR complex suppressing the activity of key transcription factors, notably Nuclear Factor Kappa-B ( NF-kappa B), which is a major factor in the initiation of inflammatory gene transcription. This mechanism targets the core genetic instructions for inflammation, resulting in the reduced synthesis of pro-inflammatory chemicals like cytokines and mediators that affect vascular tone. This overall cellular regulatory effect results in the modulation of local vascular and cellular signaling, contributing to the stabilization of endothelial barrier function and reduced vascular exudation.

Dosage and Administration Information

How to Use Dermacrin A 1%

Official Administration Guidelines

Dermacrin A 1% is a topical medication, meaning its administration is restricted to application directly onto the skin. The medicine is supplied as an ointment, which dictates the required physical administration method. The administration route is topical only, which aligns with the pharmaceutical classification of similar dermatological anti-inflammatory agents.

Dosing and Frequency Patterns

The standard approach involves applying a thin film of the ointment sufficient only to cover the affected skin surface. The dosing frequency is often characterized by an application of twice daily, frequently defined as once every 12 hours. Some regimens involve an adjustment up to three or four times daily, depending on the specific prescribing pattern.

Treatment Duration and Specific Conditions

Administration is intended for short-term use and is typically discontinued once the skin condition is controlled. The overall course of treatment is generally constrained to a finite period, such as a maximum of four consecutive weeks. The ointment is to be applied to clean, dry skin, and it is classified for external use only. A critical administration condition is the avoidance of occlusive dressings or bandages, unless explicitly directed by a healthcare professional.

Population-Specific Use

Regarding specific populations, administration guidelines stipulate that the lowest effective dosage for the shortest duration be used, a principle emphasized when the product is administered to pediatric patients. If a dose is missed, it is applied as soon as possible, or skipped entirely if the next dose is scheduled soon, to resume the regular frequency pattern.

Recent Clinical Evidence

Dermacrin A 1%: Recent Clinical Evidence

Clinical investigations of Dermacrin A 1% ointment primarily focus on its use in managing inflammatory skin conditions such as eczema (atopic dermatitis), dermal pruritus, and neurodermatitis. Studies suggest the topical application may contribute to suppressing inflammation, which can lead to relief from associated symptoms like erythema (redness), edema (swelling), and itching.

Efficacy Outcomes

Controlled studies comparing Dermacrin A 1% to placebo or other topical agents often use clinical scoring systems, such as the Investigator's Global Assessment (IGA) or a reduction in the Eczema Area and Severity Index (EASI), to measure treatment response. Findings have indicated that the 1% formulation was associated with a statistically notable improvement in these objective measures over a specified treatment period, typically ranging from two to four weeks. However, direct, large-scale, head-to-head comparative trials against all classes of topical treatments (e.g., potent corticosteroids or calcineurin inhibitors) are generally limited.

Safety and Tolerability

The established safety profile of Dermacrin A 1% is based on data from clinical trials. The most frequently reported adverse events are typically localized to the application site and are described as transient (temporary). These can include symptoms such as mild skin irritation, pruritus, or a sensation of burning. The incidence of severe systemic side effects following appropriate topical use is considered low in the documented literature. Long-term safety data, particularly regarding the potential for skin thinning or other structural changes with continuous daily use, requires careful monitoring and interpretation by a qualified healthcare professional. Consistent with standard guidelines, patients are advised to discuss any developing adverse reactions with their provider.

Frequently Asked Questions (FAQ)

Common questions about Dermacrin A 1% (FAQ)

Q: How quickly does Dermacrin A 1% typically start working?

Studies and official information measuring treatment response for Dermacrin A 1% often cover a specified period. Noticeable improvement in objective clinical measures is typically seen over a course ranging from two to four weeks of use.

Q: What happens if I stop using Dermacrin A 1% suddenly?

Administration is intended to be discontinued once the skin condition is controlled, as noted in official documents. Regulatory instructions state that the medicine should not be stopped unless directed by a doctor, who can provide guidance regarding the discontinuation of use.

Q: How long can a person safely use Dermacrin A 1%?

The maximum suggested duration of continuous treatment is generally constrained to a finite period, such as a maximum of four consecutive weeks. For use extending beyond this period, official documents state that careful monitoring by a qualified healthcare professional is required.

Q: Will Dermacrin A 1% interact with common pain relievers like ibuprofen?

Official documents do not explicitly list specific known interactions between Dermacrin A 1% and common pain relievers like ibuprofen. However, regulatory guidance mandates that patients inform their doctor and pharmacist of all medicinal products, including over-the-counter drugs, before starting co-use.

Q: Is Dermacrin A 1% safe to use during pregnancy according to official sources?

Official regulatory assessments state that use is not recommended during pregnancy. This caution is based on a lack of sufficient human safety data for the topical route and the known properties of the molecule.

Q: Can men and women use Dermacrin A 1% for the same conditions?

Official labeling specifies restrictions for pregnant and breastfeeding women, but there are no regulatory statements suggesting gender-based differences in use for adults. Eligibility is generally described as allowed for all adults (18 years and older) who do not have any contraindications.

Q: What is the earliest age for which Dermacrin A 1% is described as appropriate?

The safety and efficacy of this prescription topical formulation are not established in the pediatric population (children and adolescents). Use is generally described in official documents as allowed for adults, which typically refers to individuals 18 years and older.

Q: Is it acceptable to use Dermacrin A 1% when breastfeeding, according to regulatory information?

Regulatory assessments do not recommend use while breastfeeding. This recommendation is based on a lack of sufficient human safety data for the topical route.

Q: Can I use Dermacrin A 1% if I have a history of eczema?

Clinical investigations of Dermacrin A 1% primarily focus on its use in managing inflammatory skin conditions, including eczema (atopic dermatitis). Its purpose is described as providing relief from the core symptoms of skin irritation associated with such conditions.

Q: What is the risk of overdose if too much Dermacrin A 1% is applied?

Accidental use of more than the directed dose requires consultation with a doctor or pharmacist, as stated in regulatory guidelines. The active ingredient is associated with a high-level systemic safety constraint involving the potential for a condition resembling pseudohyperaldosteronism, which is the context for the warning against excessive exposure.

Q: Is Dermacrin A 1% available without a prescription in some countries?

Dermacrin A 1% is defined as a prescription topical pharmaceutical preparation. The availability status and classification (prescription or over-the-counter) are determined by the specific regulatory body in each country.

Q: Is it normal to feel a slight burning sensation when first applying Dermacrin A 1%?

The documented adverse events associated with the application site include a sensation of burning or local irritation. Regulatory notes indicate that this effect, when it occurs following appropriate topical use, is usually temporary in nature.

Q: Is Dermacrin A 1% the same as other 'retinoid' type products?

Dermacrin A 1% contains Enoxolone, which is classified as a dermatological anti-inflammatory agent and a pentacyclic triterpenoid derivative. Official information indicates that this pharmacological classification is distinct from retinoid-type products.

Q: Are there known interactions between Dermacrin A 1% and herbal remedies?

Regulatory documentation mandates that patients inform their doctor and pharmacist of all other medicinal products. This constraint also applies to over-the-counter medicines, dietary supplements, and any other preparation being taken, which includes herbal remedies.

Q: Do people often report feeling tired or dizzy after using Dermacrin A 1%?

The active molecule is associated with a safety constraint involving the potential for a condition resembling pseudohyperaldosteronism, which can involve increased blood pressure. Official guidelines note that patients may discuss any developing adverse reactions, such as feeling dizzy or tired, with their provider.

Q: What should I do if I get Dermacrin A 1% in my eyes?

Official instructions specify that this medicine is classified for external use only and is explicitly not intended for ophthalmic use. It is a mandatory constraint not to use this medicine for your eyes.

Q: Is Dermacrin A 1% associated with any long-term health risks described in official warnings?

Long-term safety data requires careful monitoring for potential structural skin changes, such as skin thinning (atrophy), with continuous daily use. Treatment is generally constrained to a maximum of four consecutive weeks of continuous use, and continued use beyond this must be monitored.

Q: What happens if Dermacrin A 1% is exposed to heat?

Official storage requirements mandate that the product be stored away from direct sunlight, heat, and moisture to preserve its quality and stability. These storage requirements are in place to preserve the product’s quality and stability, and deviations may result in discoloration or loss of intended characteristics.

Q: Is Dermacrin A 1% recommended for people with severe allergies?

Official labeling states that patients with a known hypersensitivity or allergy to the active ingredient, Enoxolone, or to any excipient in the ointment, are contraindicated (should not use the medicine).

Q: Why is Dermacrin A 1% sold as an ointment rather than a gel or solution?

The medicine is typically formulated as an ointment. This formulation is preferred for dry, irritated skin conditions, as the ointment vehicle provides an additional moisturizing and protective layer that helps calm the affected area.

Q: Does using more Dermacrin A 1% make it work faster?

The administration principle stipulates using only a thin film of the ointment and the lowest effective dosage for the shortest duration. Regulatory documents note that applying a dose that is too large or too frequent may increase the likelihood of unwanted side effects or skin irritation.

Q: Can Dermacrin A 1% be used for conditions not specifically listed on the label?

The medicine is indicated for use in managing specific inflammatory skin conditions, such as eczema, dermal pruritus, and neurodermatitis, as specified in the official regulatory labeling.

How should Dermacrin A 1% be stored and disposed of?

Official Storage and Disposal Requirements

To preserve the quality of Dermacrin A 1%, specific storage conditions must be followed as stated in regulatory documents.

Storage Conditions

Condition	Requirement
Child Safety	Keep out of the reach of children.
Environmental Protection	Store away from direct sunlight, heat, and moisture.
Stability Warning	Do not expose the medicine to air for a long time, as this may cause the product to become discolored.

Disposal Instructions

Any remainder of the product must be discarded after use. It is a mandatory instruction not to store any remaining portion of the Dermacrin A 1% ointment or cream. These requirements define how the product must be protected and handled after the course of treatment is finished.

Dermacrin A 1%